Biogen (BIIB) Long-Term Debt Issuances (2012 - 2025)

Biogen (BIIB) posted Long-Term Debt Issuances of -$300000.0 for Q3 2025, up 99.82% on a QoQ basis from -$170.0 million in Q4 2021.

Analysis

Biogen (BIIB) Long-Term Debt Issuances (2012 - 2025) Analysis & Trends

Biogen has reported Long-Term Debt Issuances for 8 years, with the latest figure at -$300000.0 in Q3 2025.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to -$300000.0 in Q3 2025; TTM through Dec 2025 was -$300000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $1.7 billion, changed N/A from the prior year.
Long-Term Debt Issuances was -$300000.0 for Q3 2025 at Biogen, up from -$170.0 million in the prior quarter.
The five-year high for Long-Term Debt Issuances was $169.3 million in Q1 2021, with the low at -$170.0 million in Q4 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Amgen	210.97 Bn	196.98 Bn	7.24 Bn	-
2	Gilead Sciences	180.98 Bn	177.80 Bn	6.22 Bn	1.32 Bn
3	Vertex Pharmaceuticals	132.09 Bn	124.24 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	82.56 Bn	74.57 Bn	3.93 Bn	-
5	Argenx Se	61.71 Bn	56.53 Bn	1.37 Bn	-
6	Moderna	54.60 Bn	49.46 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	34.02 Bn	30.71 Bn	992.69 Mn	-
8	Biogen	31.25 Bn	29.97 Bn	1.96 Bn	-
9	Roivant Sciences	29.76 Bn	29.76 Bn	1.16 Mn	-
10	Insmed	28.18 Bn	27.02 Bn	358.27 Mn	-

Historic Data

Download Data